Related Experiment Video
Updated: Jul 9, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Aldosterone antagonism in heart failure
1University of Florida, Division of Cardiology, Jacksonville, FL 32209, USA. alan.miller@jax.ufl.edu
Vascular Health and Risk Management
|December 15, 2007
Summary
Aldosterone antagonists, like spironolactone and eplerenone, significantly reduce mortality in patients with heart failure. These findings support their use in advanced chronic heart failure and post-myocardial infarction patients with reduced ejection fraction.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Aldosterone, a neurohormone, influences electrolyte balance and is increasingly recognized for its role in heart failure progression, especially in systolic dysfunction.
- Aldosterone antagonists have emerged as a therapeutic strategy for managing heart failure.
Purpose of the Study:
- To review clinical trial evidence supporting the use of aldosterone antagonists in heart failure management.
- To highlight the efficacy of spironolactone and eplerenone in reducing mortality and hospitalizations.
Main Methods:
- Review of major clinical trials including the Randomized Aldactone Evaluation Study (RALES) and the Eplerenone Post-myocardial infarction Heart failure Efficacy and SUrvival Study (EPHESUS).
- Analysis of outcomes in patients with symptomatic chronic advanced heart failure and post-myocardial infarction heart failure with reduced ejection fraction.
Main Results:
- Spironolactone significantly reduced mortality in symptomatic chronic advanced heart failure patients compared to placebo in the RALES study.
- Eplerenone significantly reduced mortality and hospitalizations in post-myocardial infarction patients with heart failure in the EPHESUS study.
Conclusions:
- Aldosterone antagonist therapy is beneficial for patients with chronic advanced heart failure.
- Aldosterone antagonists are effective in post-myocardial infarction patients with heart failure and reduced ejection fraction, reducing mortality and hospitalizations.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...